(IEX) IDEX Corporation Company Overview

What does IDEX Corporation do?

IDEX Corporation is a diversified industrial technology company rather than a single-product manufacturer. The company designs and manufactures engineered components and applied solutions used in life sciences, analytical instruments, water and wastewater systems, energy, industrial manufacturing, semiconductors, space and defense, fire suppression, rescue tools, dispensing, and severe-duty clamping. IDEX describes itself as a global engineered products company with three primary segments and a purpose of creating trusted solutions that improve lives on its official company profile.

Which end markets does it serve?

The simplest way to understand IDEX is to view it as a portfolio of niche businesses built around precision movement, measurement, sealing, optics, fluidics, safety and dispensing. In many of its markets, the product is small relative to the customer’s finished system but important to reliability. A chromatography instrument, semiconductor inspection tool, wastewater-monitoring network, fire truck or rescue system cannot tolerate a weak pump, valve, optical filter or control component.

How does IDEX make money?

IDEX earns revenue mainly by selling engineered products, components and systems to OEMs and end users. The company’s investor overview emphasizes proprietary technology, high-value markets, an 8020 operating model, organic growth investment, acquisitions, dividends and repurchases. That matters because IDEX is not primarily a recurring-subscription company. Its economics come from installed technical know-how, application engineering, price-cost management, product mix, operating productivity and disciplined capital deployment.

What is the revenue engine?

The revenue model is product-led, with some service and monitoring content. In FY2025, IDEX reported that about 95% of revenue was recognized at a point in time and about 5% over time. That means most sales depend on orders, shipments, customer capex cycles and OEM production schedules, while a smaller portion reflects longer project or service performance obligations.

Segment mix, engineered niches, and the 8020 operating model

IDEX reports three segments: Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety/Diversified Products. The FY2025 Form 10-K shows total net sales of $3.46B, up 6% from FY2024, with HST becoming the largest revenue segment. The most useful student takeaway is that the largest segment is not the highest-margin segment: FMT generated less revenue than HST in FY2025, but reported the highest segment adjusted EBITDA margin.

Which segment generates the most revenue?

HST is strategically important because it touches faster-growth technology markets. IDEX’s official HST page describes precision fluidics, optical components, coatings, analytical instrumentation, diagnostics, drug discovery, food and pharma, medical and dental, and semiconductor and electronics applications. The official FMT page emphasizes pumps, valves, flow meters and injectors for chemical, industrial, water, agriculture, food and energy uses. The official FSDP page describes fire suppression, rescue tools, stainless steel banding, dispensing, metering and mixing systems for colorants, paints and ingredients. Those three official segment pages are useful starting points for mapping the operating model: HST, FMT and FSDP.

How do HST, FMT and FSDP differ?

The segment split reveals IDEX’s strategic tension. HST gives the company exposure to data center power, semiconductor, space and defense, diagnostics and advanced materials. FMT anchors cash generation in fluid handling and water markets. FSDP adds differentiated safety, rescue and dispensing franchises, but its growth can be project-timing sensitive. The 8020 framework attempts to concentrate resources where IDEX sees the best combination of growth, margins and defensible specialization.

What did IDEX's latest quarter show?

The freshest official operating signal is Q1 2026. In its first-quarter 2026 earnings release, IDEX reported record orders of $988.3M, net sales of $886.9M, gross profit of $398.1M, net income attributable to IDEX of $120.0M and adjusted diluted EPS of $2.00 for the three months ended March 31, 2026. Reported sales grew 9%, organic sales grew 5% and organic orders grew 10%.

What changed in Q1 2026?

Which segment drove the latest growth?

HST was the clear Q1 2026 growth driver. HST net sales increased 17%, including 11% organic growth, while FMT grew 4% reported and 2% organically, and FSDP grew 2% reported but declined 1% organically. Management attributed HST organic growth to higher volumes in AI-driven data center power and semiconductor markets, plus strength in space and defense, partly offset by lower life sciences volume.

How financially strong is IDEX through the industrial cycle?

IDEX’s financial profile is stronger than a simple cyclical-industrials label suggests, but it is not immune to capex cycles. The FY2025 Form 10-K reported net sales of $3.46B, gross profit of $1.54B, operating income of $699.3M, net income attributable to IDEX of $483.2M and diluted EPS of $6.41. Annual organic sales increased only 1%, which shows why mix, pricing and productivity matter as much as headline revenue growth. The company’s FY2025 Form 10-K also showed free cash flow of $616.8M after $63.6M of capital expenditures.

What do margins and cash flow say?

What does the balance sheet support?

The balance sheet supports a portfolio strategy: capex is modest relative to sales, while acquisitions, dividends and repurchases are recurring uses of capital. At December 31, 2025, IDEX reported a 2.9-to-1 current ratio, $580.0M of cash and $568.6M of remaining availability under its revolving facility. This gives the company options, but the same model requires discipline because goodwill was $3.39B at March 31, 2026 and intangible assets were $1.20B.

Strategic turning points that still shape IDEX today

IDEX’s history matters because the company’s current model is the result of portfolio selection. It began as a collection of manufacturing businesses and evolved into a more focused portfolio of advantaged industrial niches. Themost important strategic question is not whether IDEX can acquire companies; it is whether acquisitions deepen proprietary technologies and fit the 8020 discipline.

What did 1988, Mott and Micro-LAM change?

1. 1988
   IDEX began from entrepreneurial manufacturing businesses, creating the foundation for a decentralized portfolio of specialized industrial companies.
2. 1990s
   The portfolio expanded into pumps, fire and safety, flow control and specialty engineered products, forming the logic behind today’s diversified segment structure.
3. 2010s
   The company increasingly moved toward life-science, fluidics, optics and engineered component niches where application knowledge can defend margins.
4. 2023
   IDEX divested Micropump and Novotema, showing that portfolio pruning is part of the model, not just acquisitions.
5. 2024
   Mott entered the HST segment, adding porous metal and engineered filtration exposure to medical, energy, industrial technology, semiconductor, water, and space and defense markets.
6. 2025
   Micro-LAM was added to HST, strengthening advanced material-processing and precision optics capabilities.
7. 2026
   Q1 2026 showed the payoff from selected end markets: HST organic sales grew 11%, driven by data center power, semiconductor, space and defense demand.

Why does 8020 matter?

The 8020 operating model is IDEX’s management system for concentrating resources on the most attractive customers, applications, products and markets. In practical terms, that means cutting complexity, reallocating engineering and sales effort, and protecting margin quality. The risk is that pruning can under-support smaller niches or cause restructuring costs; the benefit is that the company avoids being dragged into low-return volume for its own sake.

What gives IDEX a competitive advantage?

IDEX’s moat is not a single consumer brand or a massive network effect. It is a collection of smaller advantages: application engineering, installed technical reputation, qualification with OEMs, niche product breadth, decentralized speed, capital allocation and the ability to raise price where a component’s reliability matters more than its purchase price. In its markets, failure cost can be high even when the IDEX component is a small part of the customer’s total bill of materials.

Which competitors pressure the model?

Because IDEX spans fluid handling, optics, life-science components, safety, dispensing and industrial systems, it does not have one clean peer. Based on the disclosed product categories, the competitive set can include diversified industrial and specialty-technology companies such as Dover, Ingersoll Rand, ITT, Parker-Hannifin, Nordson, Teledyne, Halma and Danaher-related life-science platforms, depending on the niche. The important point is not any one rival; it is whether IDEX can maintain differentiation inside many small markets at once.

Who owns IDEX stock, and why does governance matter?

IDEX has a conventional public-company ownership profile: no founder-controlled dual-class structure dominates the vote. The 2026 proxy statement shows that directors, nominees and executive officers as a group beneficially owned 394,659 shares, or about 0.5% of common stock, as of March 12, 2026. The larger influence comes from institutional holders. The 2026 DEF 14A proxy statement listed Vanguard, Wellington and BlackRock as beneficial owners above 5%.

How does ownership shape the investor profile?

Governance still matters because IDEX’s strategy depends on acquisition discipline, portfolio pruning and incentive design. The official leadership page identifies Eric D. Ashleman as CEO and President and Sean M. Gillen as Senior Vice President and Chief Financial Officer on the company leadership page. For investors, the key governance question is whether management continues to allocate cash toward higher-return niches without overpaying for growth.

What opportunities and risks could change IDEX's outlook?

The opportunity side of the IDEX case is concentrated in higher-growth niches: AI-related data center power, semiconductor consumables, space and defense, municipal water, life-science and diagnostic components, and advanced material-processing technologies. Q1 2026 made that visible because HST organic sales grew 11% while overall organic sales grew 5%. The risk side is equally company-specific: IDEX sells into many cyclical capital-spending channels, uses acquisitions to upgrade the portfolio, and operates globally with exposure to tariffs, FX, supply chains and end-market timing.

Which growth drivers are most important?

Which filing risks matter most?

Why does IDEX matter for valuation and what should readers monitor?

For valuation, IDEX is best modeled as a high-quality industrial compounder with cyclical exposure, not as a pure growth platform. The relevant DCF drivers are organic growth, segment mix, adjusted EBITDA margin, free cash flow conversion, reinvestment needs, acquisition returns, working-capital intensity and terminal margin durability. The latest official 10-Q gives the current balance-sheet and cash-flow base: for the quarter ended March 31, 2026, IDEX reported cash of $586.2M, long-term borrowings net of $1.87B, operating cash flow of $103.7M and capex of $17.7M in its Q1 2026 Form 10-Q.

Which drivers matter in a DCF?